eligibility_summary
Adults 18–75 with confirmed stage III–IVB NPC (squamous), candidates for radical chemoradiation, ECOG 0–1, ≥1 measurable lesion (RECIST 1.1), and adequate blood counts and renal/hepatic function, consent. Exclude prior immuno/targeted therapy, recent trial, other cancers, immunodeficiency, uncontrolled disease, HIV/hepatitis/TB, recent/planned major surgery, drug allergy, pregnancy/lactation or no contraception, investigator deems unsuitable, unwilling, or live vaccines <30d.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06026878: Phase 3 RCT in locally advanced nasopharyngeal carcinoma testing GNT induction (gemcitabine + nimotuzumab + toripalimab) vs GP (gemcitabine + cisplatin) before chemoradiotherapy. Drugs/mechanisms: Gemcitabine (antimetabolite, nucleoside analog) inhibits ribonucleotide reductase and incorporates into DNA, blocking replication in proliferating tumor cells. Nimotuzumab (anti-EGFR IgG1 monoclonal antibody) blocks ligand binding and EGFR signaling (RAS/RAF/MEK/ERK, PI3K/AKT), inhibiting proliferation and enhancing radiosensitivity, can mediate ADCC against EGFR+ cells. Toripalimab (anti–PD-1 IgG4 checkpoint inhibitor) restores T‑cell activity against tumor. Cisplatin (platinum agent) forms DNA crosslinks inducing apoptosis. Targets/pathways: tumor DNA synthesis/damage, EGFR-driven signaling in NPC cells, and PD‑1/PD‑L1 immune checkpoint on T cells/tumor microenvironment.